agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha
Company profile
Ticker
SER
Exchange
Website
CEO
Michael West
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
NeuroAirmid Therapeutics, Inc. • ReCyte Therapeutics, Inc. • Reverse Bioengineering, Inc. • UniverXome Bioengineering, Inc. • Canaria Transaction Corporation ...
IRS number
821436829
SER stock data
Latest filings (excl ownership)
8-K
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
17 Apr 24
8-K
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
1 Apr 24
8-K
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
22 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
Material Modifications to Rights of Security Holders
14 Mar 24
425
Business combination disclosure
7 Mar 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
7 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
424B3
Prospectus supplement
14 Feb 24
EFFECT
Notice of effectiveness
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 497.00 k | 497.00 k | 497.00 k | 497.00 k | 497.00 k | 497.00 k |
Cash burn (monthly) | (no burn) | 5.75 k | 785.33 k | (no burn) | 621.33 k | 589.08 k |
Cash used (since last report) | n/a | 38.23 k | 5.22 mm | n/a | 4.13 mm | 3.92 mm |
Cash remaining | n/a | 458.77 k | -4.72 mm | n/a | -3.63 mm | -3.42 mm |
Runway (months of cash) | n/a | 79.8 | -6.0 | n/a | -5.8 | -5.8 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 0 |
Closed positions | 2 |
Increased positions | 11 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 3.35 bn |
Total shares | 88.71 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Juvenescence | 82.00 mm | $59.86 mm |
Broadwood Capital | 3.00 mm | $2.04 bn |
Ibs Capital | 1.88 mm | $4.67 mm |
Vanguard | 698.41 k | $474.92 mm |
Prescott General Partners | 185.19 k | $125.93 mm |
Sigma Planning | 181.39 k | $123.34 mm |
Bridgeway Capital Management | 144.77 k | $98.44 mm |
Geode Capital Management | 140.99 k | $95.90 mm |
BLK Blackrock | 131.95 k | $89.72 mm |
Strategic Wealth Designers | 92.60 k | $62.97 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Simba Gill | Stock Option Common Stock | Grant | Acquire A | No | No | 11.01 | 295,300 | 3.25 mm | 295,300 |
1 Apr 24 | Remy Gross | Stock Option Common Stock | Grant | Acquire A | No | No | 11.828 | 40,000 | 473.12 k | 157,219 |
1 Apr 24 | J Milton Harris | Stock Option Common Stock | Grant | Acquire A | No | No | 11.828 | 40,000 | 473.12 k | 110,332 |
1 Apr 24 | Richard Peter Marshall | Stock Option Common Stock | Grant | Acquire A | No | No | 11.828 | 40,000 | 473.12 k | 40,000 |
Press releases
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
22 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AGE, GRPH, FIXX
27 Feb 24
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE
27 Feb 24